DUBLIN–(BUSINESS WIRE)–The “Diabetes
Drug Intelligence Center (2012-2023)” report has been added to ResearchAndMarkets.com’s
offering.
The Diabetes Drug Intelligence Center (IC) is a global
intelligence database on diabetes drugs that covers data for 25 major
countries. It covers 13 years of comparable data, with a five-year
forecast, including value, volume sales, price, and price per capita
expenditure.
The intelligence center enhances your understanding of the diabetes
drugs industry, along with the economic factors impacting the diabetes
drugs usage, such as diabetic population levels for Type 1 and Type 2
diabetes, and obesity, which will provide you with actionable business
insights.
Scope
-
The diabetes drugs market data, volume, and value analytics with
growth trend (2012-2023). - Branded and generic drugs sales data for 2012-2023.
-
Additional information includes diabetic population levels, diabetes
prevalence, Type-1 diabetic population levels, Type-2 diabetic
population levels, and per capita expenditure.
The Diabetes Drug Intelligence Center (IC) provides exhaustive
coverage (countries covered account for more than 80% of the overall
spending on diabetes), covering and tracking of over 18,000 data points
of the diabetes drugs industry that covers various category, segments,
active pharmaceutical ingredients (API), and brands.
Market Overview
The global diabetes drugs market is expected to reach USD 94 billion by
2023 at a CAGR of 5.65%, during the forecast period.
The insulin segment of the market studied holds the highest market share
and it is mostly consolidated by leading companies, like Sanofi, Novo
Nordisk, and Eli Lilly, who account for more than 80% of the insulin
supply globally. Each of these companies has established their brands in
the market. However, due to high competitions in the local markets,
consumer penetration for their products is being worked on continuously.
Global Rise in Diabetic Population
-
There has been a tremendous increase in the diabetic population levels
globally, over the last decade. Several reports and surveys documented
a drastic increase in the diabetic population levels, based on the
changing lifestyle and habits. -
Extensive urbanization in various parts of the world is considered to
be the primary cause of obesity, health deterioration, physical
inactivity, etc. Owing to these factors, the prevalence of Type-2
diabetes mellitus (T2DM) has increased significantly. -
It is estimated that out of the total 415 million people suffering
from diabetes worldwide, 46% of this demographic is those with
undiagnosed diabetes. - Oral insulin drugs will boost the diabetes drugs market
-
Biocon is developing Insulin Tregopil, an oral prandial insulin
tablet, for the treatment of Type-1 and Type-2 diabetes mellitus. The
fast-acting oral insulin may improve post-prandial glucose control
with reduced side effects and greater adherence, thus, holding the
promise to transform Type-1 diabetes management. -
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company,
focused on the development of oral drug delivery systems, is working
to bring the first oral insulin product to market, thus, providing a
more convenient, effective, and safer method for delivering insulin
therapy.
Categories
Insulin
- Basal Insulin or Long-acting Insulin
- Bolus Insulin or Fast-acting Insulin
- Pre-mixed Insulin or Combination Insulin
- Traditional Human Insulin
- Traditional Human Insulin Biosimilars
- Insulin Glargine Biosimilars
Non-insulin Injectable
- GLP-1 Agonist Market
- Amylin Analogue
Oral Anti-diabetics Drugs
- Dopamine -D2 Receptor Agonist
- Meglitinide
- Alpha-Glucosidase Inhibitors
- SGLT2 Inhibitors
- Biguanides
- Sulfonylureas
- DPP-4 Inhibitors
Combination Drugs
- Insulin Combinations
- Oral Combinations
Reasons to Purchase this Dashboard
-
More Granular: Covers more categories, segments, and information on
brands at country- and global levels than the other market
intelligence providers -
Provides an outlook of the market with the recent market data and
historical data and market forecast -
Ease of Comparability: Our analytics is based on standardized
definition across the world to facilitate better comparability of
market data -
View the market in different ways among categories and geographies, in
order to understand where the actual opportunity lies -
Market segmentation including quantitative research incorporating the
impact of economic and non-economic aspects -
Regional- and country- level data integrating the demand and supply
forces that are influencing the growth of the market -
Market value (in USD million) and volume (in tablet or ml million)
data for each segment and sub-segment -
Understanding of the market, considering the value and volume changes,
and intra-category competition - Dedicated analyst support for research queries and training
-
Continuous amendment of the yearly database with significant changes
updated based on scenarios
Companies Mentioned
- Astellas
- AstraZeneca
- Boehringer Ingelheim
- Bristol Myers Squibb
- Eli Lilly
- Janssen Pharmaceuticals
- Merck and Co.
- Novartis
- Novo Nordisk
- Pfizer
- Sanofi
- Takeda
Topics Covered
1. Introduction
1.1 Key Deliverables of the Study
1.2 Market Definition
2. Research Approach and Methodology
2.1 Introduction
2.2 Research Designs
2.3 Study Phases
2.3.1 Internal sources evaluation
2.3.2 Research Process
2.3.3 Modeling & triangulation
2.3.4 Data finalization
2.3.5 Expert Validation
3. Market Segmentation
3.1 By Drug
3.1.1 Oral anti-diabetic drugs
3.1.2 Insulin
3.1.3 Non-Insulin Injectable drugs
3.1.4 Combination Drugs
3.2 Geography
3.2.1 North America
3.2.2 Europe
3.2.3 Latin America
3.2.4 Asia-Pacific
3.2.5 Middle East and Africa
4. Market Indicators
4.1 Type-1 Diabetes population (2012-2023)
4.2 Type-2 Diabetes population (2012-2023)
5. Company Share Analysis
For more information about this report visit https://www.researchandmarkets.com/research/gqkqt5/diabetes_drug?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs, Diabetes
Drugs